The influence of prostaglandin antagonists on radiation therapy of carcinoma of the cervix.
In a random trial of 160 women undergoing radiation therapy for carcinoma of the cervix of all stages 76 individuals were treated with 3 X 100 mg oxyphenbutazone daily and 84 individuals served as controls. Reevaluation shows a significantly better 5- and 10-year-survival rate of 70 and 62% in the treatment group, compared to 55 and 44% in the control group. The mode of action of oxyphenbutazone consists of the inhibition of prostaglandin synthesis. Improvement of survival rates is explained by two theories: (1) slowing of tumor spread by inhibition of necessary prostaglandins; and (2) improvement of cell repair after radiation therapy.
D003131:Combined Modality Therapy; D015232:Dinoprostone; D005260:Female; D006801:Humans; D008875:Middle Aged; D010113:Oxyphenbutazone / Q000627:therapeutic use*; D011458:Prostaglandins E / Q000037:antagonists & inhibitors*; D011897:Random Allocation; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*
D011458:Prostaglandins E; D010113:Oxyphenbutazone; D015232:Dinoprostone